Stay updated with breaking news from Start Forms. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
• VYJUVEK™ approved in the U.S. as the first and only topical redosable gene therapy for the treatment of dystrophic epidermolysis bullosa • 121 Patient Start Forms in the first six weeks of...
Operator: Good day, and welcome to the Travere Therapeutics First Quarter 2023 Financial Results and Corporate Update Conference Call. Today's conference is being recorded.
14.7 million in net revenue for the third quarter 2021 Steady increases in LUPKYNIS Patient Start Forms, Conversion Rates and Payer Coverage Addition of two preclinical assets with potential in rare autoimmune conditions to grow and diversify the pipeline Conference call to be hosted today at 8:30 a.m. ET Aurinia Pharmaceuticals Inc. today issued its financial results for the third quarter ended September 30, 2021. ...
ALNY earnings call for the period ending September 30, 2021.